On June 27, 2008, Cardium Therapeutics, Inc., a Delaware corporation ("Cardium"), entered into a Securities Purchase Agreement with an institutional investor that participated in its prior financing for the purchase of 1,625,000 shares, in the aggregate, of its common stock, $0.0001 par value per share, at a purchase price of $2.00 per share, and five year warrants to purchase up to an additional 568,750 shares of its common stock at an exercise price of $2.00 (collectively, the "Financing"). The warrants were fully exercisable when issued.

The Financing closed on June 27, 2008. At closing, Cardium issued the shares and the warrants and received gross proceeds of approximately $3,250,000 (before placement agent fees and offering expenses and excluding any proceeds that Cardium may receive upon exercise of the warrants). Cardium plans to pay off the principal balance on its commercial credit facility out of proceeds, thereby retiring its remaining debt obligations to Life Sciences Capital.

Empire Asset Management Company ("Empire") acted as financial advisor and the sole placement agent for the Financing pursuant to the terms of a Placement Agent Agreement by and between Cardium and Empire and will receive from the gross proceeds of the Financing a commission equal to approximately $211,250, or 6.5% of the gross proceeds received by Cardium in the Financing, and a warrant to purchase approximately 97,500 shares of Cardium's common stock, or 6.0% of the number of shares sold in the Financing at an exercise price of $2.29 and otherwise substantially on the same terms as the warrants issued to the purchasers in the Financing. In addition, pursuant to the terms of the Securities Purchase Agreement, Cardium has agreed to reimburse one of the purchasers the amount of $17,500 for such purchaser's legal fees and expenses.

Pursuant to the terms of the warrants to be issued in the Financing, the exercise price and/or the number of shares issuable upon exercise of the warrants are subject to adjustment in the event of certain specified issuances of equity securities or rights, distributions, or transactions.

The foregoing description of the Securities Purchase Agreement, the warrants, and the Placement Agent Agreement do not purport to be complete and are qualified in their entirety by the forms of warrant attached hereto as Exhibits 4.1 and 4.2, the form of Securities Purchase Agreement attached hereto as Exhibit 10.1, the Placement Agent Agreement attached hereto as Exhibit 10.2, and the Amendment to Placement Agent Agreement attached hereto as Exhibit 10.3, each of which are incorporated herein by reference.

On June 30, 2008, Cardium issued a press release announcing the Financing. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

(d) Exhibits.

 4.1   Form of Investor Warrant (issued to the purchasers at the closing of the
       Financing)

 4.2   Form of Placement Agent Warrant (to be issued to Empire)

10.1   Form of Securities Purchase Agreement, dated June 27, 2008, by and between
       Cardium Therapeutics, Inc. and each purchaser (an agreement on
       substantially this form was signed by each purchaser in the Financing)

10.2   Placement Agent Agreement dated June 20, 2008, by and between Cardium
       Therapeutics, Inc. and Empire Asset Management Company

10.3   Amendment to Placement Agent Agreement dated June 27, 2008, by and between
       Cardium Therapeutics, Inc. and Empire Asset Management Company

99.1   Press Release of Cardium Therapeutics, Inc. issued on June 30, 2008